#biosciences
Vyome Holdings Dives into $57 Billion Immunology Market with Selective JAK Inhibitor Licensing Deal from Tata’s Impetis Biosciences
Mumbai/New York – Nasdaq-listed Vyome Holdings has made a significant strategic move, licensing two preclinical selective Janus kinase...
